Pharynx Cancer Recruiting Phase 1 / 2 Trials for Ipilimumab (DB06186)

IndicationStatusPhase
DBCOND0031604 (Pharynx Cancer)Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03749460Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland CancersTreatment